Anderson-Fabry disease in AustriaMorbus Fabry in Österreich

被引:0
作者
Matthias Lorenz
Anna-Christina Hauser
Margot Püspök-Schwarz
Peter Kotanko
Ingrid Arias
Herbert Zodl
Reinhard Kramar
Eduard Paschke
Till Voigtländer
Gere Sunder-Plassmann
机构
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] University of Vienna,Department of Dermatology
[3] Lehrkrankenhaus der Karl-Franzens-Universität Graz,Department of Internal Medicine, Krankenhaus der Barmherzigen Brüder
[4] Krankenanstalt Rudolfstiftung,Third Department of Medicine
[5] Krankenhaus Wiener Neustadt,Second Department of Internal Medicine
[6] Krankenhaus der Kreuzschwestern,Third Department of Medicine
[7] University of Graz,Department of Pediatrics
[8] University of Vienna,Institute of Neurology
来源
Wiener Klinische Wochenschrift | 2003年 / 115卷
关键词
Lysosomal storage diseases; Fabry disease; enzyme replacement therapy; end-stage renal disease; Lysosomale Speicherkrankheiten; Morbus Fabry; Enzymersatztherapie; terminale Niereninsuffizienz;
D O I
暂无
中图分类号
学科分类号
摘要
Fabry disease is an X-linked inherited inborn error of glycosphingolipid catabolism. The deficiency of α-galactosidase A leads to the deposition of glycosphingolipids primarily in lysosomes of blood vessel cells. In classically affected hemizygotes clinical manifestations include pain in the extremities, vessel ectasia (angiokeratoma) in skin and mucous membranes, ophtalmological abnormalities, and hypohidrosis. As disease progresses there is renal, cardiac, cerebral and vascular involvement, with most patients experiencing renal insufficiency, cardiac hypertrophy or stroke. Many female carriers of Fabry disease also have symptoms. Recently available enzyme replacement therapy has the potential to control or even reverse disease progression.
引用
收藏
页码:235 / 240
页数:5
相关论文
共 211 条
  • [1] Colombi A(1967)Angiokeratoma corporis diffusum — Fabry’s disease Helv Med Acta 34 67-83
  • [2] Kostyal A(2001)Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes J Inherit Metab Dis 24 715-724
  • [3] Bracher R(1974)Evolution of X-chromosome inactivation in mammals Nature 250 651-653
  • [4] Gloor F(1977)Evidence for preferential X-chromosome inactivation in a family with Fabry disease Am J Hum Genet 29 361-370
  • [5] Mazzi R(1979)The ocular manifestations in Fabry’s disease Arch Ophthalmol 97 671-676
  • [6] Tholen H(2001)Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females J Med Genet 38 769-775
  • [7] Whybra C(2002)Cardiac manifestations of Anderson-Fabry disease in heterozygous females J Am Coll Cardiol 40 1668-1674
  • [8] Kampmann C(1973)Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes J Lab Clin Med 81 157-171
  • [9] Willers I(2001)Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 2743-2749
  • [10] Davies J(2001)Safety and efficacy of recombinant human alpha-galactosidase A — replacement therapy in Fabry’s disease N Engl J Med 345 9-16